Skip to content

EV / sales at other companies

Merck & Co. logo
Merck & Co.MRK
5.2×+1.2×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
5.5×+0.6×
Ocular Therapeutix logo
Ocular TherapeutixOCUL
24.1×+9.2×
HRO
HarrowHROW
5.7×-0.6×
Theravance Biopharma logo
Theravance BiopharmaTBPH
5.4×-0.5×
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
2.7×-4.0×

Other financials

Income statement

See full
Revenue$696.0K-97.2%
Gross profit$9.8M-30.1%
Operating income-$87.2M-78.6%
Net income-$84.8M-87.7%
EPS (diluted)-$0.99-52.3%

Balance sheet

See full
Cash & equivalents$77.7M-8.7%
Total debt$22.3M-7.3%
Total equity$230.5M-22.8%
Total assets$288.2M-20.5%

Cash flow

See full
Operating cash flow-$80.5M-51.6%
CapEx$997.0K+261%
Free cash flow-$81.5M-52.7%

Valuation

See full
Market cap$1.21B+108%
Enterprise value$1.15B+122%
P/S158.5×+148×

Profitability

See full
Operating margin-3,700.9%-4,042pp
Net margin-3,566.6%-3,874pp
FCF margin-3,565.9%-3,884pp

Returns & leverage

See full
Return on equity-102.7%+1,157pp
Debt / equity0.1×0.0×
Current ratio6.7×-1.2×

Where this comes from

Calculated from EyePoint, Inc. ’s reported figures.

Based on the most recent quarter.

The official record: EyePoint, Inc. ’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about EyePoint, Inc. 's ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is EyePoint, Inc. 's EV / sales?
EyePoint, Inc. (EYPT) reported EV / sales of 134× in Q1 2026.
How has EyePoint, Inc. 's EV / sales changed year-over-year?
EyePoint, Inc. 's EV / sales increased by 2310.4% year-over-year, from 5.6× to 134×.
What is the long-term trend for EyePoint, Inc. 's EV / sales?
Over 5 years (2020 to 2025), EyePoint, Inc. 's EV / sales has grown at a 48.3% compound annual growth rate (CAGR), from 6.4× to 45.7×.
What does EV / sales mean?
Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.